Immunocore (IMCR) director William Pao receives grant of 27,492 options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Immunocore Holdings plc director William Pao received a new stock option grant. The award covers 27,492 options to buy Ordinary Shares at an exercise price of $28.52 per share, expiring on May 26, 2036.

The options vest at the earlier of May 27, 2027, or the day immediately before Immunocore’s next annual general meeting, as long as Pao remains in continuous service through the vesting date. Following this grant, he holds 27,492 share options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pao William

Role null

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	27,492	$0.00	--

Holdings After Transaction: Share Option (Right to Buy) — 27,492 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 27,492 options Exercise price: $28.52 per share Expiration date: May 26, 2036 +2 more

5 metrics

Options granted 27,492 options Grant to director William Pao on May 27, 2026

Exercise price $28.52 per share Share Option (Right to Buy) for Ordinary Shares

Expiration date May 26, 2036 Option term end for granted share options

Vesting date Earlier of May 27, 2027 or pre-AGM Vesting contingent on continuous service

Post-grant derivative holdings 27,492 options Total derivative securities following transaction

Key Terms

Share Option (Right to Buy), exercise price, vesting, annual general meeting, +1 more

5 terms

exercise price financial

"conversion_or_exercise_price: "28.5200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to the option award shall vest at the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual general meeting financial

"the day immediately prior to the date of the Issuer's next annual general meeting"

derivative securities financial

"derivativeTransactionCount": 1"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

Form 4 Insider Transactions: What Each Field Means →

05/28/2026 - 07:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pao William

(Last)

(First)

(Middle)

C/O IMMUNOCORE HOLDINGS PLC

92 PARK DRIVE, MILTON PARK

(Street)

ABINGDON

OXFORDSHIRE

OX14 4RY

(City)

(State)

(Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunocore Holdings plc [ IMCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (Right to Buy)	$28.52	05/27/2026		A		27,492		⁽¹⁾	05/26/2036	Ordinary Shares	27,492	$0	27,492	D

Explanation of Responses:

1. The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Lily Hepworth, Attorney-in-Fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Immunocore (IMCR) director William Pao report on this Form 4?

He reported receiving a grant of 27,492 stock options. These options give him the right to buy Immunocore Ordinary Shares at a fixed price, reflecting equity-based compensation rather than an open-market share purchase or sale.

How many Immunocore (IMCR) options were granted to William Pao and at what price?

William Pao was granted 27,492 share options with an exercise price of $28.52 per share. This means he can buy Immunocore Ordinary Shares at that fixed price once the options vest and before they expire.

When do William Pao’s Immunocore (IMCR) stock options vest?

The options vest on the earlier of May 27, 2027, or the day immediately before Immunocore’s next annual general meeting. Vesting is contingent on his continuous service with the company through the applicable vesting date.

When do the Immunocore (IMCR) options granted to William Pao expire?

The granted stock options expire on May 26, 2036. After this expiration date, any unexercised options will lapse, meaning they can no longer be used to purchase Immunocore Ordinary Shares at the stated exercise price.

Did William Pao buy or sell Immunocore (IMCR) shares in the market?

No market buy or sell took place; this filing reports a grant of options. The transaction is classified as a grant or award acquisition, reflecting compensation, not an open-market purchase or sale of existing shares.

How many Immunocore (IMCR) derivative securities does William Pao hold after this grant?

After this transaction, William Pao holds 27,492 derivative securities in the form of share options. These options represent the right to acquire an equivalent number of Immunocore Ordinary Shares upon exercise, subject to vesting and expiration terms.